An analysis presented at Kidney Week 2012 showed type 2 diabetes patients who took linagliptin were 16% less likely to develop micro- and macroalbuminuria, chronic kidney disease and acute renal failure and showed lower risk of all-cause mortality compared with those in the placebo group.